What is included in reference safety information?
Reference Safety Information (RSI) is a document containing a cumulative list of all the adverse events observed during a clinical trial. The document details the seriousness/non-seriousness of the adverse events along with the description of their nature, and frequency.
Does an investigator brochure need a signature page?
A signature page is not required and is left to the Sponsor’s discretion. The Investigator’s Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of these product(s) in human subjects.
What does investigator brochure contain?
Investigator’s Brochure (IB) is a document which contains all the available clinical and non-clinical data on the Investigational Product(s) that are known and relevant to the study of the product.
What are some key elements included in the investigators brochure?
7.2 General Considerations The IB should include: This should provide the sponsor’s name, the identity of each investigational product (i.e., research number, chemical or approved generic name, and trade name(s) where legally permissible and desired by the sponsor), and the release date.
What is RSI in pharmacovigilance?
Reference Safety Information (RSI) defines which reactions are expected for the Investigational Medicinal Product (IMP) being administered to subjects participating in a clinical trial.
What is CCDS in pharma?
The Company Core Data Sheet (CCDS) serves as a key document representing the pharmaceutical company’s position on the product and is used as a reference document for national labels.
Is IRB approval investigator brochure?
It is common that the Investigator’s Brochure is submitted to the IRB, and the IRB may establish written procedures which require its submission. Investigator’s Brochures may be part of the investigational plan that the IRB reviews when reviewing medical device studies.
When should a DSUR be submitted?
The DSUR should be submitted to all concerned regulatory agencies no later than 60 calendar days after the DSUR data lock point.
What is the purpose of investigator brochure?
The purpose of the IB is to compile data relevant to studies of the IP in human subjects gathered during preclinical and other clinical trials. An IB is intended to provide the investigator with insights necessary for management of study conduct and study subjects throughout a clinical trial.
What is investigator brochure in pharmacovigilance?
What is investigator brochure Slideshare?
The Investigator’s Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial. Read more.
What is the purpose of the investigator brochure?
The purpose of the IB is to compile data relevant to studies of the investigational product in human subjects gathered during preclinical and other clinical trials to provide the investigator with information necessary for the management of study conduct and study subjects throughout a clinical trial.
What is Listedness in pharmacovigilance?
Listedness/Unlistedness: any reaction which is not included in the Company Core Safety Information within a company’s core data sheet for a marketed product is unlisted. If it is included it is termed listed.
What is a core safety data sheet?
More Definitions of Company Core Data Sheet Company Core Data Sheet is an unofficial working document prepared by marketing authorization holders typically containing material relating to safety, indications, dosing, pharmacology, and other information concerning the product.
What is CCDS labeling?
When should I submit DSUR?
Sponsors are required to submit a DSUR within one year of the Development International Birth Date (DIBD – the date of first authorisation of a clinical trial in any country worldwide) and provide annual DSUR submissions until all open clinical studies have ended (the final clinical study is completed and its study …
What is the difference between PSUR and Pader?
The EU requires pharmaceutical companies to file a periodical safety update report (PSUR), which is also used in many other countries. In the U.S., the FDA requires organizations to file a periodic adverse drug experiences report (PADER).
What is reference safety information (RSI)?
Reference Safety Information (RSI) defines which reactions that are expected for the Investigational Medicinal Product (IMP) being administered to subjects participating in a clinical trial.
What should be included in the RSI section of a clinical trial?
If the best document to support the conduct of the trial is the IB, the RSI section should be written in compliance with safety reporting requirements for clinical trials (a list of serious adverse reactions considered expected for safety reporting purposes).
What is an investigator’s brochure?
INVESTIGATOR’S BROCHURE The Investigator’s Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product (s) that are relevant to the study of the product (s) in human subjects.
Is the Investigators Brochure the same as the RSI?
Remember the entire Investigators Brochure (IB) is not the RSI, but a clearly defined section of it should be if an IB is the option used. The same also applies for the SmPC, it should be clear you are referring to section 4.8.